Arixtra is indicated for the prophylaxis of deep vein thrombosis.
Mylan will pay $225 million to acquire the rights for commercialization, marketing and intellectual property. Another $75 million is contingent upon satisfaction of certain conditions.
More articles on acquisitions:
3 recent hospital transactions and partnerships
J&J seeks buyer for medical device business
Covidien acquires medical device firm Sapheon
